DXS International PLC, together with its subsidiaries, develops and distributes clinical decision support solutions to general practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. More Details
Undervalued with solid track record.
Share Price & News
How has DXS International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 7EE is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: Insufficient data to determine 7EE's volatility change over the past year.
7 Day Return
DE Healthcare Services
1 Year Return
DE Healthcare Services
Return vs Industry: Insufficient data to determine how 7EE performed against the German Healthcare Services industry.
Return vs Market: Insufficient data to determine how 7EE performed against the German Market.
Long-Term Price Volatility Vs. Market
How volatile is DXS International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is DXS International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 7EE (€0.09) is trading below our estimate of fair value (€0.23)
Significantly Below Fair Value: 7EE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 7EE is good value based on its PE Ratio (7.7x) compared to the DE Healthcare Services industry average (51.8x).
PE vs Market: 7EE is good value based on its PE Ratio (7.7x) compared to the German market (28.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 7EE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 7EE is good value based on its PB Ratio (0.9x) compared to the DE Healthcare Services industry average (4.3x).
How is DXS International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DXS International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has DXS International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 7EE has high quality earnings.
Growing Profit Margin: 7EE's current net profit margins (13.5%) are higher than last year (6.6%).
Past Earnings Growth Analysis
Earnings Trend: 7EE's earnings have grown by 5.6% per year over the past 5 years.
Accelerating Growth: 7EE's earnings growth over the past year (107%) exceeds its 5-year average (5.6% per year).
Earnings vs Industry: 7EE earnings growth over the past year (107%) exceeded the Healthcare Services industry 11.3%.
Return on Equity
High ROE: 7EE's Return on Equity (11.6%) is considered low.
How is DXS International's financial position?
Financial Position Analysis
Short Term Liabilities: 7EE's short term assets (£1.5M) exceed its short term liabilities (£845.1K).
Long Term Liabilities: 7EE's short term assets (£1.5M) exceed its long term liabilities (£1.0M).
Debt to Equity History and Analysis
Debt Level: 7EE's debt to equity ratio (14.5%) is considered satisfactory.
Reducing Debt: 7EE's debt to equity ratio has increased from 0.6% to 14.5% over the past 5 years.
Debt Coverage: 7EE's debt is well covered by operating cash flow (193.1%).
Interest Coverage: 7EE's interest payments on its debt are well covered by EBIT (7.3x coverage).
What is DXS International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 7EE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 7EE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 7EE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 7EE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 7EE's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
David Immelman (63 yo)
Mr. David A. Immelman is Founder and Chief Executive Officer of DXS International plc and has been its Director since July 17, 2007. He has continued steering DXS to become an accredited supplier to the NH...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
DXS International PLC's company bio, employee growth, exchange listings and data sources
- Name: DXS International PLC
- Ticker: 7EE
- Exchange: BST
- Founded: 2007
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: €3.965m
- Shares outstanding: 43.33m
- Website: https://www.dxs-systems.co.uk
Number of Employees
- DXS International PLC
- Wrecclesham House
- Wrecclesham Road
- GU10 4PS
- United Kingdom
DXS International PLC, together with its subsidiaries, develops and distributes clinical decision support solutions to general practitioners, nurses, and retail pharmacies in the United Kingdom and South A...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/14 21:31|
|End of Day Share Price||2021/04/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.